Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMRX
SellImmuneering Corporation · Healthcare · United States · $323M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Immuneering Corporation is a clinical-stage oncology company focused on developing translational medicines that target the MAPK pathway to treat solid tumors. The company's competitive moat is anchored by its proprietary Disease-Canceling Technology (DCT) platform, which designs medicines to selectively target cancer cells while sparing healthy tissue. It operates as a specialized biotechnology player aiming to overcome drug resistance in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.3M | 0 | 0 | 0 | — | — | — | 17.1M | 121.9% |
| EPS | -0.78 | -0.85 | -0.98 | -1.27 | — | -0.93 | -1.11 | -1.29 | — |
| Shares | 64.7M | 64.7M | 64.7M | 64.6M | -0.1% | 64.7M | — | — | — |
| Debt | 4.8M | 4.5M | 4.2M | 3.8M | -7.6% | 3.6M | — | — | — |
| Equity | 109.9M | 90.6M | 41.4M | 218.5M | 25.8% | — | — | — | — |
| Op CF | -44.1M | -49.0M | -55.0M | -45.3M | — | -56.8M | — | — | — |
| Inv CF | 41.8M | 7.3M | 26.4M | -88.7M | — | — | — | — | — |
| Fin CF | 19.0K | 28.4M | 5.3M | 226.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMRX | Immuneering Corporation(you) | $323M | 21 | Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 20 | Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $360M | 22 | Sell |
| FATE | Fate Therapeutics, Inc. | $291M | 22 | Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 21 | Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 18 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 19 | Strong Sell |
| IPSC | Century Therapeutics, Inc. | $367M | 23 | Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 22 | Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 17 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%